Genomic determinants of cancer immunotherapy. (August 2016)

• Record Type: Journal Article
• Authors: Miao, Diana; Van Allen, Eliezer M
• Is Part Of: Current opinion in immunology. Volume 41(2016)
• Page Start: 32
• Page End: 38
• Publication Date: 2016-08
• Subjects: Immunology -- Periodicals; Allergy -- Periodicals; Immunology -- Abstracts -- Periodicals; Allergy -- Abstracts -- Periodicals; 616.079
• DOI: 10.1016/j.coi.2016.05.010
• Languages: English
• ISSNs: 0952-7915

Abstract

Graphical abstract: Highlights: Cancer immunotherapies yield survival benefits in subsets of patients across cancer types. Tumor-specific antigens and gene expression signatures may mediate therapeutic benefit. Genomically guided studies may improve efficacy of and prediction of response to immunotherapy. Abstract : Cancer immunotherapies — including therapeutic vaccines, adoptive cell transfer, oncolytic viruses, and immune checkpoint blockade — yield durable responses in many cancer types, but understanding of predictors of response is incomplete. Genomic characterization of human cancers has already contributed to the success of targeted therapies; in cancer immunotherapy, identification of tumor-specific antigens through whole-exome sequencing may be key to designing individualized, highly immunogenic therapeutic vaccines. Additionally, pre-treatment tumor mutational and gene expression signatures can predict which patients are most likely to benefit from cancer immunotherapy. Continued work in harnessing genomic, transcriptomic, and immunological data from clinical cohorts of immunotherapy-treated patients will bring the promises of precision medicine to immuno-oncology.